CY1122248T1 - Μιγμα λιπαρων οξεων προς χρηση στη θεραπευτικη αγωγη φλεγμονωδων παθολογιων - Google Patents

Μιγμα λιπαρων οξεων προς χρηση στη θεραπευτικη αγωγη φλεγμονωδων παθολογιων

Info

Publication number
CY1122248T1
CY1122248T1 CY20191101148T CY191101148T CY1122248T1 CY 1122248 T1 CY1122248 T1 CY 1122248T1 CY 20191101148 T CY20191101148 T CY 20191101148T CY 191101148 T CY191101148 T CY 191101148T CY 1122248 T1 CY1122248 T1 CY 1122248T1
Authority
CY
Cyprus
Prior art keywords
acid
mixture
fatty acids
inflammatory diseases
therapeutic treatment
Prior art date
Application number
CY20191101148T
Other languages
English (en)
Inventor
Lodovico BURATTIN
Original Assignee
Again Life Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48227394&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122248(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Again Life Italia Srl filed Critical Again Life Italia Srl
Publication of CY1122248T1 publication Critical patent/CY1122248T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ένα μίγμα από τουλάχιστον τρία λιπαρά οξέα που επιλέγονται από παλμιτικό οξύ, ελαϊκό οξύ, στεατικό οξύ, λινελαϊκό οξύ, άλφα-λινολενικό οξύ, γάμμα-λινολενικό οξύ, εικοσαπενταενοϊκό οξύ (EPA), εικοσιδυαεξαενοϊκό οξύ (DHA), αζελαϊκό οξύ και μυριστικό οξύ. Η παρούσα εφεύρεση αναφέρεται επίσης στη χρήση του προαναφερθέντος μίγματος, στη θεραπευτική αγωγή φλεγμονωδών παθολογιών.
CY20191101148T 2013-03-08 2019-11-05 Μιγμα λιπαρων οξεων προς χρηση στη θεραπευτικη αγωγη φλεγμονωδων παθολογιων CY1122248T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361774796P 2013-03-08 2013-03-08
IT000354A ITMI20130354A1 (it) 2013-03-08 2013-03-08 Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
PCT/EP2014/054163 WO2014135529A1 (en) 2013-03-08 2014-03-04 Mixture of fatty acids for use in the treatment of inflammatory pathologies

Publications (1)

Publication Number Publication Date
CY1122248T1 true CY1122248T1 (el) 2020-11-25

Family

ID=48227394

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191101148T CY1122248T1 (el) 2013-03-08 2019-11-05 Μιγμα λιπαρων οξεων προς χρηση στη θεραπευτικη αγωγη φλεγμονωδων παθολογιων
CY20201100229T CY1122783T1 (el) 2013-03-08 2020-03-16 Μιγμα λιπαρων οξεων (ομαδα λιπαρων οξεων, ο.λ.ο.) προς χρηση στη θεραπευτικη αγωγη φλεγμονωδων παθολογιων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100229T CY1122783T1 (el) 2013-03-08 2020-03-16 Μιγμα λιπαρων οξεων (ομαδα λιπαρων οξεων, ο.λ.ο.) προς χρηση στη θεραπευτικη αγωγη φλεγμονωδων παθολογιων

Country Status (18)

Country Link
US (2) US11020365B2 (el)
EP (2) EP2964215B1 (el)
AU (2) AU2014224710B2 (el)
CA (1) CA2904112C (el)
CY (2) CY1122248T1 (el)
DK (2) DK3219316T3 (el)
EA (2) EA036724B1 (el)
ES (2) ES2753257T3 (el)
HK (1) HK1243924A1 (el)
HR (2) HRP20191963T1 (el)
HU (2) HUE048361T2 (el)
IT (1) ITMI20130354A1 (el)
LT (2) LT2964215T (el)
PL (2) PL3219316T3 (el)
PT (2) PT2964215T (el)
RS (2) RS59523B1 (el)
SI (2) SI2964215T1 (el)
WO (1) WO2014135529A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20130354A1 (it) 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
JP7118642B2 (ja) * 2014-08-08 2022-08-16 アリ リサーチ ソシエタ ア レスポンサビリタ リミタータ センプリフィカタ 炎症性およびアレルギー性病変の治療に用いるための脂肪酸とパルミトイルエタノールアミドの混合物
AR102008A1 (es) * 2015-09-24 2017-01-25 Brix S R L Ingrediente farmacéutico activo (ifa) oleoso para el tratamiento de afecciones de la piel, composiciones que lo comprenden y su uso para prepararlas
CN112469406B (zh) * 2018-05-31 2024-05-17 财团法人峨山社会福祉财团 硬脂酸用于预防或治疗肺纤维化的用途
KR102204097B1 (ko) * 2019-01-31 2021-01-18 동신대학교 산학협력단 지방산을 유효성분으로 포함하는 천식 예방 또는 치료용 조성물
JP2023513759A (ja) * 2020-02-12 2023-04-03 レトロトップ、 インコーポレイテッド 化粧品用途のための重水素化多価不飽和脂肪酸またはそのエステル
AU2022328181A1 (en) * 2021-08-09 2024-03-21 Kentucky Equine Research, Inc. Compositions and methods for modulating equine fatty acid profiles
AU2022396538A1 (en) * 2021-11-24 2024-03-21 Jenivision Inc. Delivery methods for treating brain and central nervous system diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY24246A1 (es) 1995-06-06 1996-06-14 Neutrogena Corp Vehiculos tropicos que contienen acido azelaico solubilizado y estabilizado
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
DE10161729A1 (de) 2001-12-15 2003-06-18 Mira Ursic Medizinische bzw. pharmazeutische Salbenzubereitung
DE50211883D1 (de) 2002-04-30 2008-04-24 Cognis Ip Man Gmbh Verwendung von Wirkstoffmischungen mit Azelainsäure und Glycyrrhetinsäure als Anti-Aknemittel
US7612111B2 (en) * 2003-03-20 2009-11-03 Imagenetix, Inc. Esterified fatty acid composition
US20080057552A1 (en) * 2006-08-31 2008-03-06 Inmok Lee Processes for Producing Fats or Oils and Compositions Comprising the Fats or Oils
NZ552238A (en) 2006-12-20 2009-07-31 Seperex Nutritionals Ltd An extract
JP4512881B2 (ja) * 2007-11-27 2010-07-28 築 中島 薬用油脂
US8765661B2 (en) * 2008-03-20 2014-07-01 Virun, Inc. Compositions containing non-polar compounds
US20090264520A1 (en) 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
DK2349250T3 (en) * 2008-10-31 2017-07-03 Lipid Pharmaceuticals Ehf Fatty acids for use as a medicament
US9062275B2 (en) 2009-04-17 2015-06-23 Natac Pharma, S.L. Compositions rich in omega-3 fatty acids with a low content in phytanic acid
PL2475352T5 (pl) 2009-09-07 2019-02-28 Epitech Group S.P.A. Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji
CA2703532C (en) 2010-05-10 2018-05-01 Eva Turley Topically administered, skin-penetrating glycosaminoglycan formulations suitable for use in cosmetic and pharmaceutical applications
DE102010021671A1 (de) 2010-05-27 2011-12-01 Intendis Gmbh Azelainsäurehaltige Formulierung mit Pigmentzusatz
RS61153B1 (sr) 2011-01-07 2020-12-31 Anji Pharma Us Llc Ligand hemosenzornog receptora-osnovne terapije
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
ITMI20130354A1 (it) 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.

Also Published As

Publication number Publication date
AU2018202190B2 (en) 2019-05-02
EA201791885A1 (ru) 2018-01-31
PL3219316T3 (pl) 2020-06-01
RS59523B1 (sr) 2019-12-31
AU2018202190A1 (en) 2018-04-26
ES2753257T3 (es) 2020-04-07
HUE046239T2 (hu) 2020-02-28
WO2014135529A1 (en) 2014-09-12
RS60023B1 (sr) 2020-04-30
US20160015666A1 (en) 2016-01-21
ITMI20130354A1 (it) 2014-09-09
LT3219316T (lt) 2020-04-10
SI2964215T1 (sl) 2019-12-31
HUE048361T2 (hu) 2020-08-28
EP2964215A1 (en) 2016-01-13
EP3219316A1 (en) 2017-09-20
CY1122783T1 (el) 2021-05-05
US20210290578A1 (en) 2021-09-23
DK3219316T3 (da) 2020-03-16
CA2904112C (en) 2021-03-23
EP3219316B1 (en) 2020-02-19
AU2014224710B2 (en) 2018-04-12
HRP20191963T1 (hr) 2020-01-24
EP2964215B1 (en) 2019-08-21
US11020365B2 (en) 2021-06-01
PL2964215T3 (pl) 2020-03-31
HK1243924A1 (zh) 2018-07-27
EA035091B1 (ru) 2020-04-27
PT2964215T (pt) 2019-11-12
EA036724B1 (ru) 2020-12-11
HRP20200394T1 (hr) 2020-06-12
PT3219316T (pt) 2020-03-27
CA2904112A1 (en) 2014-09-12
EA201591680A1 (ru) 2015-12-30
LT2964215T (lt) 2019-11-25
DK2964215T3 (da) 2019-11-11
SI3219316T1 (sl) 2020-07-31
ES2779851T3 (es) 2020-08-20
AU2014224710A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
CY1122248T1 (el) Μιγμα λιπαρων οξεων προς χρηση στη θεραπευτικη αγωγη φλεγμονωδων παθολογιων
CY1120663T1 (el) Dpa-εμπλουτισμενες συνθεσεις ωμεγα-3 πολυακορεστων λιπαρων οξεων σε μορφη ελευθερου οξεος
CL2019003105A1 (es) Lípidos extraídos de plantas que comprenden ácidos grasos poliinsaturados de cadena larga. (divisional solicitud 201601560)
WO2014074552A3 (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
CO2017001088A2 (es) Mezcla de ácidos grasos y palmitoiletanolamida para su uso en el tratamiento de patologías inflamatorias y alérgicas
MX2016004487A (es) Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados.
EA201400152A1 (ru) Микроорганизмы, продуцирующие эйкозапентаеновую кислоту, композиции, содержащие жирные кислоты, и способы их получения и применения
MX2015008199A (es) Formulaciones de acido eicosapentaenoico (epa).
WO2016040570A3 (en) Dietary emulsion formulations and methods for using the same
CY1123942T1 (el) Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα
MX2019007771A (es) Composiciones alimenticias para mascotas.
CO2017005911A2 (es) Método para incrementar niveles de ácidos grasos de omega-3 en productos de carne de res por medio de administración de una dieta de pasto y algas
PT2435039E (pt) Combinação de uma fonte de leucina e uma fonte de ácido gordo insaturado omega-3 para uso no tratamento de hipercalcemia
PH12017500738A1 (en) Feeding algae to cattle at low doses to produce high omega 3 levels in beef
TW201613571A (en) OMWGA-3 compositions, dosage forms, and methods of use
AR095832A1 (es) Composición farmacéutica oral útil para el trastorno del déficit de atención e hiperactividad, suplemento nutricional y alimento que la comprenden y proceso para preparar la composición
GB201607617D0 (en) Use of EPA and DHA Omega3 Dietary supplementation and Omega6 polyunsaturated fatty acid dietary restriction to cure 2 type diabetes
UA102174U (uk) Спосіб лікування артеріальної гіпертензії у поєднанні з остеоартрозом та ожирінням
AR116761A2 (es) Lípido que comprende ácidos grasos poliinsaturados de cadena larga
MX2019009337A (es) Eficacia a largo plazo de tratamiento de enfermedad hepatica con epa y dha.
RU2011122400A (ru) Амиды полиненасыщенных жирных кислот, снижающие агрегацию тромбоцитов
RU2012118888A (ru) Способ лечения метаболического синдрома у больных артериальной гипертонией
MY178598A (en) Process for producing super hard palm based fraction
UA106430U (uk) Спосіб оцінки впливу деяких антиоксидантів на жирнокислотну формулу ліпідів тканин експериментальних щурів
MY178497A (en) Super hard palm oil based fraction